Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cost-effectiveness of different strategies to prevent breast and ovarian cancer in German women with a BRCA 1 or 2 mutation.

The European journal of health economics : HEPAC : health economics in prevention and care - 1 Apr 2018

Müller Dirk, Danner Marion, Rhiem Kerstin, Stollenwerk Björn, Engel Christoph, Rasche Linda, Borsi Lisa, Schmutzler Rita, Stock Stephanie

Abstract excerpt

BACKGROUND: Women with a BRCA1 or BRCA2 mutation are at increased risk of developing breast and/or ovarian cancer. This economic modeling study evaluated different preventive interventions for 30-year-old women with a confirmed BRCA (1 or 2) mutation. METHODS: A Markov model was developed to estimate the costs and benefits [i.e., quality-adjusted life years (QALYs), and life years gained (LYG)] associated with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Breast Neoplasms
Share to Cost-Benefit Analysis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to BRCA2 gene

Share to Genes, BRCA1

Share to Genes, BRCA2

Share to Mutation

Share to Ovarian Neoplasms

Share to Quality-Adjusted Life Years

Source

Identifiers

PMID: 28382503
DOI: 10.1007/s10198-017-0887-5

Genes

BRCA1
BRCA2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cost-effectiveness of different strategies to prevent breast and ovarian cancer in German women with a BRCA 1 or 2 mutation.PMID 28382503Read ↗

Decision-analytic evaluation of the comparative effectiveness and cost-effectiveness of strategies to prevent breast and ovarian cancer in German women with BRCA-1/2 mutations.Semantic proximity Read ↗

Cost-utility analysis of risk-reducing strategies to prevent breast and ovarian cancer in BRCA-mutation carriers in Switzerland.Semantic proximity Read ↗

Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation.Semantic proximity Read ↗

A MDP model for breast and ovarian cancer intervention strategies for BRCA1/2 mutation carriers.Semantic proximity Read ↗

Comparative effectiveness of screening and prevention strategies among BRCA1/2-affected mutation carriers.Semantic proximity Read ↗

Prevention with tamoxifen or other hormones versus prophylactic surgery in BRCA1/2-positive women: a decision analysis.Semantic proximity Read ↗

Life expectancy gains from cancer prevention strategies for women with breast cancer and BRCA1 or BRCA2 mutations.Semantic proximity Read ↗

Cost-Effectiveness of BRCA 1/2 Genetic Test and Preventive Strategies: Using Real-World Data From an Upper-Middle Income CountrySemantic proximity Read ↗

Decision analysis of prophylactic surgery or screening for BRCA1 mutation carriers: a more prominent role for oophorectomy.Semantic proximity Read ↗

A Cost-Effectiveness Evaluation of Germline BRCA1 and BRCA2 Testing in UK Women with Ovarian Cancer.Semantic proximity Read ↗

Testing for the BRCA1 and BRCA2 breast-ovarian cancer susceptibility genes: a decision analysis.Semantic proximity Read ↗

Decision analysis of prophylactic mastectomy and oophorectomy in BRCA1-positive or BRCA2-positive patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.